Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Megan A. Hatlen"'
Autor:
Oleg Schmidt-Kittler, Michael Sheets, Yoon-Koo Kang, Chandrasekhar V. Miduturu, Richard D. Kim, Andy Boral, Joseph L. Kim, Nooreen Rubin, Neil Bifulco, Emily Rozsahegyi, Cori Ann Sherwin, Megan A. Hatlen, Natasja Brooijmans, Marion Dorsch, Hongliang Shi, Beni B. Wolf, Klaus P. Hoeflich, Christoph Lengauer, Timothy J. Guzi
Publikováno v:
Cancer Discovery. 9:1686-1695
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of human cancer on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfb336958095dcb0a493f3604a752c01
https://doi.org/10.1158/2159-8290.cd-19-0367
https://doi.org/10.1158/2159-8290.cd-19-0367
Autor:
Emily Rozsahegyi, Ruduan Wang, Riadh Lobbardi, Grace O. Silva, Joseph L. Kim, Dean Zhang, Victoria Tzortziou Brown, Jian Guo, Richard Vargas, Megan A. Hatlen, Marion Dorsch, Doug Wilson, Yoon Jin Choi, Rich Woessner, Phil Ramsden, Neil Bifulco, Michelle Maynard, Faith Stevison, Emanuele Perola, Rob Meissner, Klaus P. Hoeflich, Yeon Seo Choi, Tim LaBranche, Steve Wenglowsky
Publikováno v:
Cancer Research. 81:1279-1279
Background: Cyclin dependent kinases (CDK) comprise a family of proteins which are activated upon cyclin binding to promote cell cycle progression. Historically, CDK family inhibitors have had limited utility in the clinic due to 1) toxicities associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a09f8cd954d28465a9103a79c7a17d6d
https://doi.org/10.1158/1538-7445.am2021-1279
https://doi.org/10.1158/1538-7445.am2021-1279
Publikováno v:
2018 Medicinal Chemistry Reviews ISBN: 9780996293266
2018 Medicinal Chemistry Reviews
2018 Medicinal Chemistry Reviews
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6edc786e55b973d4db9d8ee44b5ec725
https://doi.org/10.29200/acsmedchemrev-v53.ch12
https://doi.org/10.29200/acsmedchemrev-v53.ch12
Autor:
Beni B. Wolf, Cori-Ann Sherwin, Natasja Brooijmans, Christoph Lengauer, Hongliang Shi, Megan A. Hatlen, Michael Sheets, Neil Bifulco, Emily Rozsahegyi, Chandra Miduturu, Yoon-Koo Kang, Marion Dorsch, Richard D. Kim, Nooreen Rubin, Klaus P. Hoeflich, Oleg Schmidt-Kittler, Andy Boral, Joseph L. Kim, Timothy J. Guzi
Publikováno v:
Molecular Cancer Therapeutics. 18:A118-A118
When on-target resistance mutations occur in response to potent and selective therapeutics, the target is often considered a validated driver of disease. Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide whose drivers re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::705d66d87fd0d1bda277b4d4b0bd2564
https://doi.org/10.1158/1535-7163.targ-19-a118
https://doi.org/10.1158/1535-7163.targ-19-a118
Autor:
Agnes Viale, Megan A. Hatlen, Magali Cavatore, Cem Meydan, Chen Wei, Martin S. Tallman, Nicholas D. Socci, Todd Hricik, Elisabeth Paietta, Ulrich Steidl, Yanwen Jiang, Brittany Woods, Stephen D. Nimer, Alan H. Shih, Luisa Cimmino, Yongming Sun, Ari Melnick, Ross L. Levine, Alexander Robertson, Suveg Pandey, Iléana Antony-Debré, Iannis Aifantis, Franck Rapaport, Laura Barreyro, Muhamed Baljevic, Elisa de Stanchina, Christopher E. Mason, Kaitlyn Shank
Publikováno v:
Cancer Cell. 27(4):502-515
Specific combinations of acute myeloid leukemia (AML) disease alleles, including FLT3 and TET2 mutations, confer distinct biologic features and adverse outcome. We generated mice with mutations in Tet2 and Flt3, which resulted in fully penetrant, let
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43b8d1bab0e8cac037bbd5b1979b576
Autor:
Stephen D. Nimer, Anthony DeBlasio, Kazunori Murata, Delphine Ndiaye-Lobry, Martin Fleisher, Takashi Asai, Elena M. Cortizas, Chen Lossos, John H.J. Petrini, Ramiro E. Verdun, Megan A. Hatlen
Publikováno v:
Scientific Reports
Multiple myeloma is a plasma cell neoplasm with an extremely variable clinical course. Animal models are needed to better understand its pathophysiology and for preclinical testing of potential therapeutic agents. Hematopoietic cells expressing the h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1010fa6928b64dcc29f27eb16a0df374
Autor:
Fan Liu, Robert G. Roeder, Yanwen Jiang, Jinsong Zhang, Haiming Xu, Stephen D. Nimer, Silvia Menendez, Tony DeBlasio, Ari Melnick, Takashi Asai, Ly P. Vu, Xinyang Zhao, Francesca Voza, Alexander Gural, Philip A. Cole, Hao Xu, Megan A. Hatlen, Xiao-Jian Sun, Lan Wang, Gang Huang, Fabiana Perna
Publikováno v:
Science. 333:765-769
The chromosomal translocations found in acute myelogenous leukemia (AML) generate oncogenic fusion transcription factors with aberrant transcriptional regulatory properties. Although therapeutic targeting of most leukemia fusion proteins remains elus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffc5dcf2774e8e3ac925f0e9452b2cf
https://doi.org/10.1126/science.1201662
https://doi.org/10.1126/science.1201662
Autor:
Fabiana Perna, Fan Liu, Hao Xu, Priya Koppikar, Stephen D. Nimer, Silvia Menendez, Lan Wang, Ayalew Tefferi, Ross L. Levine, Michael W. Harr, Megan A. Hatlen, Anthony DeBlasio, Omar Abdel-Wahab, Xinyang Zhao
Publikováno v:
Cancer Cell. 19(2):283-294
SummaryThe JAK2V617F constitutively activated tyrosine kinase is found in most patients with myeloproliferative neoplasms. While examining the interaction between JAK2 and PRMT5, an arginine methyltransferase originally identified as JAK-binding prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19ace20a3b70fda95c6c9f05bc30861
Autor:
Yurong Tan, Megan A. Hatlen, Na Man, Nolan Chastain, Feng Chun Yang, Mengyao Sheng, Stephen D. Nimer, Haiming Xu, Marta Garcia-Cao, Ronit Shah, Xiao-Jian Sun, Lan Wang, Gang Huang, Junhong Song, Guoyan Cheng, Fan Liu, Yuan Zhou, Robert Benezra, Na Liu
Publikováno v:
Blood. 127(19)
Inhibitor of DNA binding 1 (Id1) functions as an E protein inhibitor, and overexpression of Id1 is seen in acute myeloid leukemia (AML) patients. To define the effects of Id1 on leukemogenesis, we expressed MLL-AF9 in fetal liver (FL) cells or bone m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a2473e343748c484be4ee6c6a164b4
https://pubmed.ncbi.nlm.nih.gov/27206664
https://pubmed.ncbi.nlm.nih.gov/27206664
Autor:
Ewa A. Grabowska, Jacob E. Joergens, Stephen D. Nimer, Bridget Riley-Gillis, Dayna M. Oschwald, Mithat Gonen, Alan H. Shih, Willey Liao, Francesca Voza, Franck Rapaport, Ross L. Levine, Kanika Arora, Megan A. Hatlen, Michael G. Kharas, Lan Wang, Takashi Asai, Benjamin G. Neel, Vladimir Vacic, Shengqing Gu
Publikováno v:
The Journal of Experimental Medicine
Hatlen et al. provide an integrative analysis of the mutational landscape of mouse and human AML and identify functionally relevant cooperation between AML1-ETO and PTPN11 D61Y. Based on these findings, they generate a novel mouse model of t(8;21)+ A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::697a44873d55ac31b7def89a1274549c
https://pubmed.ncbi.nlm.nih.gov/26666262
https://pubmed.ncbi.nlm.nih.gov/26666262